Skip to content

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Neoplasms

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria:

* Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored study, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.
* Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.

Exclusion Criteria:

Not Applicable

Other protocol-defined inclusion/exclusion criteria apply

Study Location

Local Institution - 02801
Local Institution - 02801
Hamilton, Ontario
Canada

Contact Study Team

Local Institution - 02802
Local Institution - 02802
Vancouver, British Columbia
Canada

Contact Study Team

Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Christine Chen, Site 02301

4169464501
University Of Calgary
University Of Calgary
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Nizar Bahlis, Site 02302

4039441880
CIUSSS de l'Est-de-l'Ile-de-Montreal
CIUSSS de l'Est-de-l'Ile-de-Montreal
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Isabelle Fleury, Site 02800

5142523404
Study Sponsored By
Celgene
Participants Required
More Information
Study ID: NCT03435796